Literature DB >> 12124886

Can very high-dose anti-tumor necrosis factor blockade at onset of rheumatoid arthritis produce long-term remission?

Philip G Conaghan, Mark A Quinn, Philip O'Connor, Richard J Wakefield, Zunaid Karim, Paul Emery.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12124886     DOI: 10.1002/art.10274

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


× No keyword cloud information.
  7 in total

1.  Successes achieved and challenges ahead in translating biomarkers into clinical applications.

Authors:  Greg Tesch; Shashi Amur; John T Schousboe; Jeffrey N Siegel; Lawrence J Lesko; Jane P F Bai
Journal:  AAPS J       Date:  2010-03-16       Impact factor: 4.009

Review 2.  Treatment of rheumatoid arthritis.

Authors:  Paul Emery
Journal:  BMJ       Date:  2006-01-21

3.  Treating rheumatoid arthritis.

Authors:  Paul Emery; Tore K Kvien
Journal:  BMJ       Date:  2007-07-14

4.  Infliximab has no apparent effect in the inner ear hearing function of patients with rheumatoid arthritis and ankylosing spondylitis.

Authors:  H Toktas; E Okur; U Dundar; A Dikici; O K Kahveci
Journal:  Clin Rheumatol       Date:  2014-04-27       Impact factor: 2.980

Review 5.  Treating very early rheumatoid arthritis.

Authors:  Karim Raza; Caitriona E Buckley; Mike Salmon; Christopher D Buckley
Journal:  Best Pract Res Clin Rheumatol       Date:  2006-10       Impact factor: 4.098

Review 6.  Infliximab: 12 years of experience.

Authors:  Josef S Smolen; Paul Emery
Journal:  Arthritis Res Ther       Date:  2011-05-25       Impact factor: 5.156

7.  Coronary Artery Disease Evaluation in Rheumatoid Arthritis (CADERA): study protocol for a randomized controlled trial.

Authors:  Bara Erhayiem; Sue Pavitt; Paul Baxter; Jacqueline Andrews; John P Greenwood; Maya H Buch; Sven Plein
Journal:  Trials       Date:  2014-11-08       Impact factor: 2.279

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.